Amicus Retained Earnings from 2010 to 2024

FOLD Stock

USD 9.98 0.02 0.20%

Amicus Therapeutics' Retained Earnings are decreasing over the years with slightly volatile fluctuation. Overall, Retained Earnings are projected to go to about -2.5 B this year. Retained Earnings is the cumulative amount of net income that Amicus Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2005-12-31

Previous Quarter

-2.7 B

Current Value

-2.8 B

Quarterly Volatility

922.9 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 M, Interest Expense of 52.7 M or Other Operating Expenses of 496.5 M, as well as many indicators such as Price To Sales Ratio of 9.96, Dividend Yield of 0.0 or PTB Ratio of 27.46. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.

Check out the analysis of Amicus Therapeutics Correlation against competitors.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Latest Amicus Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Amicus Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Amicus Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (2.68 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Amicus Retained Earnings Regression Statistics

	Arithmetic Mean	(1,275,660,020)
	Coefficient Of Variation	(75.19)
	Mean Deviation	847,870,688
	Median	(1,063,610,000)
	Standard Deviation	959,190,653
	Sample Variance	920046.7T
	Range	2.7B
	R-Value	(0.98)
	Mean Square Error	40464.8T
	R-Squared	0.96
	Slope	(210,056,215)
	Total Sum of Squares	12880653.9T

Amicus Retained Earnings History

	2024	-2.5 B
	2023	-2.7 B
	2022	-2.5 B
	2021	-2.3 B
	2020	-2 B
	2019	-1.8 B
	2018	-1.4 B

Other Fundumenentals of Amicus Therapeutics

Retained Earnings Total Equity

Amicus Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Accounts Payable	Short Term Investments	Common Stock	Property Plant Equipment	Net Debt	Long Term Debt	Total Current Assets	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Debt Total	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.85	-0.61	0.88	0.49	0.63	0.72	0.59	0.49	0.63	0.84	0.51	0.53	-0.34	0.36	0.95	0.7	0.41	0.49	0.67	0.01	0.84	0.52	0.44	0.43
Total Stockholder Equity	0.85		-0.34	0.59	0.7	0.79	0.52	0.44	0.24	0.34	0.73	0.3	0.4	-0.03	0.07	0.79	0.44	0.38	0.42	0.34	0.12	0.69	0.52	0.51	0.15
Retained Earnings	-0.61	-0.34		-0.78	-0.25	-0.29	-0.97	-0.89	-0.88	-0.95	-0.8	-0.42	0.09	0.04	-0.94	-0.74	-0.94	0.31	0.22	-0.92	0.53	-0.8	-0.4	-0.26	-0.94
Total Liab	0.88	0.59	-0.78		0.26	0.33	0.84	0.67	0.64	0.81	0.75	0.61	0.51	-0.52	0.66	0.9	0.75	0.32	0.41	0.77	-0.38	0.79	0.32	0.24	0.66
Accounts Payable	0.49	0.7	-0.25	0.26		0.63	0.37	0.41	0.17	0.19	0.53	0.0	0.04	0.29	0.08	0.44	0.33	0.03	0.06	0.19	0.08	0.47	0.5	0.49	0.14
Short Term Investments	0.63	0.79	-0.29	0.33	0.63		0.42	0.34	0.47	0.38	0.76	0.06	-0.06	0.37	-0.01	0.6	0.41	-0.04	-0.01	0.42	0.35	0.63	0.74	0.76	0.05
Common Stock	0.72	0.52	-0.97	0.84	0.37	0.42		0.9	0.83	0.92	0.86	0.45	0.01	-0.05	0.86	0.83	0.93	-0.18	-0.09	0.88	-0.47	0.84	0.44	0.32	0.88
Property Plant Equipment	0.59	0.44	-0.89	0.67	0.41	0.34	0.9		0.71	0.8	0.79	0.34	-0.12	0.14	0.81	0.65	0.86	-0.31	-0.23	0.76	-0.37	0.72	0.56	0.42	0.92
Net Debt	0.49	0.24	-0.88	0.64	0.17	0.47	0.83	0.71		0.94	0.78	0.3	-0.26	0.11	0.8	0.65	0.83	-0.44	-0.37	0.92	-0.32	0.75	0.5	0.42	0.75
Long Term Debt	0.63	0.34	-0.95	0.81	0.19	0.38	0.92	0.8	0.94		0.83	0.36	-0.05	-0.09	0.87	0.75	0.88	-0.27	-0.18	0.96	-0.47	0.82	0.48	0.39	0.83
Total Current Assets	0.84	0.73	-0.8	0.75	0.53	0.76	0.86	0.79	0.78	0.83		0.28	0.01	0.12	0.57	0.87	0.88	-0.13	-0.05	0.87	-0.07	0.94	0.76	0.66	0.63
Short Term Debt	0.51	0.3	-0.42	0.61	0.0	0.06	0.45	0.34	0.3	0.36	0.28		0.49	-0.54	0.39	0.53	0.38	0.41	0.43	0.33	-0.26	0.2	0.09	0.03	0.4
Current Deferred Revenue	0.53	0.4	0.09	0.51	0.04	-0.06	0.01	-0.12	-0.26	-0.05	0.01	0.49		-0.87	-0.15	0.4	-0.09	0.95	0.96	-0.07	0.0	0.13	-0.2	-0.18	-0.15
Net Tangible Assets	-0.34	-0.03	0.04	-0.52	0.29	0.37	-0.05	0.14	0.11	-0.09	0.12	-0.54	-0.87		-0.09	-0.28	0.04	-0.78	-0.8	-0.05	0.25	-0.03	0.43	0.43	-0.02
Net Receivables	0.36	0.07	-0.94	0.66	0.08	-0.01	0.86	0.81	0.8	0.87	0.57	0.39	-0.15	-0.09		0.54	0.81	-0.39	-0.32	0.8	-0.72	0.6	0.2	0.08	0.95
Good Will	0.95	0.79	-0.74	0.9	0.44	0.6	0.83	0.65	0.65	0.75	0.87	0.53	0.4	-0.28	0.54		0.79	0.24	0.32	0.77	-0.18	0.92	0.44	0.35	0.55
Capital Surpluse	0.7	0.44	-0.94	0.75	0.33	0.41	0.93	0.86	0.83	0.88	0.88	0.38	-0.09	0.04	0.81	0.79		-0.27	-0.18	0.94	-0.28	0.86	0.53	0.36	0.86
Deferred Long Term Liab	0.41	0.38	0.31	0.32	0.03	-0.04	-0.18	-0.31	-0.44	-0.27	-0.13	0.41	0.95	-0.78	-0.39	0.24	-0.27		0.99	-0.27	0.18	-0.05	-0.24	-0.19	-0.37
Intangible Assets	0.49	0.42	0.22	0.41	0.06	-0.01	-0.09	-0.23	-0.37	-0.18	-0.05	0.43	0.96	-0.8	-0.32	0.32	-0.18	0.99		-0.18	0.14	0.03	-0.21	-0.17	-0.29
Long Term Debt Total	0.67	0.34	-0.92	0.77	0.19	0.42	0.88	0.76	0.92	0.96	0.87	0.33	-0.07	-0.05	0.8	0.77	0.94	-0.27	-0.18		-0.29	0.86	0.56	0.43	0.79
Long Term Investments	0.01	0.12	0.53	-0.38	0.08	0.35	-0.47	-0.37	-0.32	-0.47	-0.07	-0.26	0.0	0.25	-0.72	-0.18	-0.28	0.18	0.14	-0.29		-0.15	0.27	0.26	-0.55
Short Long Term Debt	0.84	0.69	-0.8	0.79	0.47	0.63	0.84	0.72	0.75	0.82	0.94	0.2	0.13	-0.03	0.6	0.92	0.86	-0.05	0.03	0.86	-0.15		0.53	0.43	0.61
Net Invested Capital	0.52	0.52	-0.4	0.32	0.5	0.74	0.44	0.56	0.5	0.48	0.76	0.09	-0.2	0.43	0.2	0.44	0.53	-0.24	-0.21	0.56	0.27	0.53		0.97	0.33
Net Working Capital	0.44	0.51	-0.26	0.24	0.49	0.76	0.32	0.42	0.42	0.39	0.66	0.03	-0.18	0.43	0.08	0.35	0.36	-0.19	-0.17	0.43	0.26	0.43	0.97		0.16
Capital Stock	0.43	0.15	-0.94	0.66	0.14	0.05	0.88	0.92	0.75	0.83	0.63	0.4	-0.15	-0.02	0.95	0.55	0.86	-0.37	-0.29	0.79	-0.55	0.61	0.33	0.16

Click cells to compare fundamentals

About Amicus Therapeutics Financial Statements

Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-2.7 B	-2.5 B
Retained Earnings Total Equity	-2.3 B	-2.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Amicus Therapeutics Correlation against competitors.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.34)

Revenue Per Share

1.629

Quarterly Revenue Growth

0.367

Return On Assets

0.0116

Return On Equity

(0.67)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Retained Earnings from 2010 to 2024

Latest Amicus Therapeutics' Retained Earnings Growth Pattern

Amicus Retained Earnings Regression Statistics

Amicus Retained Earnings History

Other Fundumenentals of Amicus Therapeutics

Amicus Therapeutics Retained Earnings component correlations

About Amicus Therapeutics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY